Gastrointestinal Cancer

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

The FDA has granted an orphan drug designation to LYT-200, a fully human IgG4 monoclonal antibody targeting galectin-9, for use as a potential therapeutic option for patients with pancreatic cancer.

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

Wasif M. Saif, MD, discusses the evolving role of PARP inhibitors and anticipated trends for research in pancreatic cancer.

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.

Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

The FDA has granted an orphan drug designation to the HER2-targeted natural killer cell engager therapy, DF1001, as a potential therapeutic option for patients with esophageal cancer.

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

Sameek Roychowdhury, MD, PhD, discusses the efficacy and safety data reported with infigratinib in FGFR2-positive cholangiocarcinoma, nuances to treatment with the agent, and ongoing research efforts to further improve outcomes in this population.

Gastrointestinal cancer is increasingly viewed through a multidisciplinary lens, and the 2021 International Society of Gastrointestinal Oncology Annual Meeting produced intriguing developments in the armamentarium.

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.

The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.

Incidence of pancreatic cancer incidence rose overall from 2000 to 2018, with a significant increase in women younger than 55 years, especially those aged 15 to 35 years.

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Although the addition of eryaspase to chemotherapy improved overall survival over chemotherapy alone in patients with metastatic pancreatic cancer, the difference in benefit was not found to be statistically significant, missing the primary end point of the phase 3 TRYbeCA-1 trial.